FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094906946> ?p ?o ?g. }

• W3094906946 endingPage "1464" @default.
• W3094906946 startingPage "1455" @default.
• W3094906946 abstract "In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial topic. As an aid to treatment decisions, we aimed to develop a prognostic assay that integrates multiple data types for predicting survival outcome in patients with newly diagnosed HER2-positive breast cancer.We derived a combined prognostic model using retrospective clinical-pathological data on stromal tumour-infiltrating lymphocytes, PAM50 subtypes, and expression of 55 genes obtained from patients who participated in the Short-HER phase 3 trial. The trial enrolled patients with newly diagnosed, node-positive, HER2-positive breast cancer or, if node negative, with at least one risk factor (ie, tumour size >2 cm, histological grade 3, lymphovascular invasion, Ki67 >20%, age ≤35 years, or hormone receptor negativity), and randomly assigned them to adjuvant anthracycline plus taxane-based combinations with either 9 weeks or 1 year of trastuzumab. Trastuzumab was administered intravenously every 3 weeks (8 mg/kg loading dose at first cycle, and 6 mg/kg thereafter) for 18 doses or weekly (4 mg/kg loading dose in the first week, and 2 mg/kg thereafter) for 9 weeks, starting concomitantly with the first taxane dose. Median follow-up was 91·4 months (IQR 75·1-105·6). The primary objective of our study was to derive and evaluate a combined prognostic score associated with distant metastasis-free survival (the time between randomisation and distant recurrence or death before recurrence), an exploratory endpoint in Short-HER. Patient samples in the training dataset were split into a training set (n=290) and a testing set (n=145), balancing for event and treatment group. The training set was further stratified into 100 iterations of Monte-Carlo cross validation (MCCV). Cox proportional hazard models were fit to MCCV training samples using Elastic-Net. A maximum of 92 features were assessed. The final prognostic model was evaluated in an independent combined dataset of 267 patients with early-stage HER2-positive breast cancer treated with different neoadjuvant and adjuvant anti-HER2-based combinations and from four other studies (PAMELA, CHER-LOB, Hospital Clinic, and Padova) with disease-free survival outcome data.From Short-HER, data from 435 (35%) of 1254 patients for tumour size (T1 vs rest), nodal status (N0 vs rest), number of tumour-infiltrating lymphocytes (continuous variable), subtype (HER2-enriched and basal-like vs rest), and 13 genes composed the final model (named HER2DX). HER2DX was significantly associated with distant metastasis-free survival as a continuous variable (p<0·0001). HER2DX median score for quartiles 1-2 was identified as the cutoff to identify low-risk patients; and the score that distinguished quartile 3 from quartile 4 was the cutoff to distinguish medium-risk and high-risk populations. The 5-year distant metastasis-free survival of the low-risk, medium-risk, and high-risk populations were 98·1% (95% CI 96·3-99·9), 88·9% (83·2-95·0), and 73·9% (66·0-82·7), respectively (low-risk vs high-risk hazard ratio [HR] 0·04, 95% CI 0·0-0·1, p<0·0001). In the evaluation cohort, HER2DX was significantly associated with disease-free survival as a continuous variable (HR 2·77, 95% CI 1·4-5·6, p=0·0040) and as group categories (low-risk vs high-risk HR 0·27, 0·1-0·7, p=0·005). 5-year disease-free survival in the HER2DX low-risk group was 93·5% (89·0-98·3%) and in the high-risk group was 81·1% (71·5-92·1).The HER2DX combined prognostic score identifies patients with early-stage, HER2-positive breast cancer who might be candidates for escalated or de-escalated systemic treatment. Future clinical validation of HER2DX seems warranted to establish its use in different scenarios, especially in the neoadjuvant setting.Instituto Salud Carlos III, Save the Mama, Pas a Pas, Fundación Científica, Asociación Española Contra el Cáncer, Fundación SEOM, National Institutes of Health, Agenzia Italiana del Farmaco, International Agency for Research on Cancer, and the Veneto Institute of Oncology, and Italian Association for Cancer Research." @default.
• W3094906946 created "2020-11-09" @default.
• W3094906946 creator A5004725639 @default.
• W3094906946 creator A5006511628 @default.
• W3094906946 creator A5008991955 @default.
• W3094906946 creator A5013497028 @default.
• W3094906946 creator A5014379154 @default.
• W3094906946 creator A5015289835 @default.
• W3094906946 creator A5016597149 @default.
• W3094906946 creator A5016992044 @default.
• W3094906946 creator A5019569585 @default.
• W3094906946 creator A5020747800 @default.
• W3094906946 creator A5021488024 @default.
• W3094906946 creator A5028384284 @default.
• W3094906946 creator A5028741920 @default.
• W3094906946 creator A5030451537 @default.
• W3094906946 creator A5034632931 @default.
• W3094906946 creator A5042649658 @default.
• W3094906946 creator A5043895722 @default.
• W3094906946 creator A5048969389 @default.
• W3094906946 creator A5051550047 @default.
• W3094906946 creator A5051629490 @default.
• W3094906946 creator A5051951830 @default.
• W3094906946 creator A5052268581 @default.
• W3094906946 creator A5053983312 @default.
• W3094906946 creator A5054811851 @default.
• W3094906946 creator A5061850497 @default.
• W3094906946 creator A5063676677 @default.
• W3094906946 creator A5068497911 @default.
• W3094906946 creator A5068906915 @default.
• W3094906946 creator A5069211092 @default.
• W3094906946 creator A5077175788 @default.
• W3094906946 creator A5077805370 @default.
• W3094906946 creator A5077942090 @default.
• W3094906946 creator A5080122151 @default.
• W3094906946 creator A5082195410 @default.
• W3094906946 creator A5085165482 @default.
• W3094906946 creator A5087336206 @default.
• W3094906946 creator A5088488154 @default.
• W3094906946 creator A5089285482 @default.
• W3094906946 creator A5089513581 @default.
• W3094906946 date "2020-11-01" @default.
• W3094906946 modified "2023-10-09" @default.
• W3094906946 title "A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation" @default.
• W3094906946 cites W1996778928 @default.
• W3094906946 cites W2006070721 @default.
• W3094906946 cites W2075894019 @default.
• W3094906946 cites W2095633632 @default.
• W3094906946 cites W2120431466 @default.
• W3094906946 cites W2125239609 @default.
• W3094906946 cites W2132619562 @default.
• W3094906946 cites W2144442992 @default.
• W3094906946 cites W2175026167 @default.
• W3094906946 cites W2352525452 @default.
• W3094906946 cites W2461625475 @default.
• W3094906946 cites W2506902454 @default.
• W3094906946 cites W2591481727 @default.
• W3094906946 cites W2624590002 @default.
• W3094906946 cites W2727635070 @default.
• W3094906946 cites W2768980003 @default.
• W3094906946 cites W2805734855 @default.
• W3094906946 cites W2806629158 @default.
• W3094906946 cites W2889673459 @default.
• W3094906946 cites W2902218997 @default.
• W3094906946 cites W2908170962 @default.
• W3094906946 cites W2928807055 @default.
• W3094906946 cites W2942862617 @default.
• W3094906946 cites W2947131352 @default.
• W3094906946 cites W2948720210 @default.
• W3094906946 cites W2972413446 @default.
• W3094906946 cites W2998950563 @default.
• W3094906946 cites W3000476524 @default.
• W3094906946 cites W3006652814 @default.
• W3094906946 doi "https://doi.org/10.1016/s1470-2045(20)30450-2" @default.
• W3094906946 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8140650" @default.
• W3094906946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33152285" @default.
• W3094906946 hasPublicationYear "2020" @default.
• W3094906946 type Work @default.
• W3094906946 sameAs 3094906946 @default.
• W3094906946 citedByCount "46" @default.
• W3094906946 countsByYear W30949069462020 @default.
• W3094906946 countsByYear W30949069462021 @default.
• W3094906946 countsByYear W30949069462022 @default.
• W3094906946 countsByYear W30949069462023 @default.
• W3094906946 crossrefType "journal-article" @default.
• W3094906946 hasAuthorship W3094906946A5004725639 @default.
• W3094906946 hasAuthorship W3094906946A5006511628 @default.
• W3094906946 hasAuthorship W3094906946A5008991955 @default.
• W3094906946 hasAuthorship W3094906946A5013497028 @default.
• W3094906946 hasAuthorship W3094906946A5014379154 @default.
• W3094906946 hasAuthorship W3094906946A5015289835 @default.
• W3094906946 hasAuthorship W3094906946A5016597149 @default.
• W3094906946 hasAuthorship W3094906946A5016992044 @default.
• W3094906946 hasAuthorship W3094906946A5019569585 @default.
• W3094906946 hasAuthorship W3094906946A5020747800 @default.
• W3094906946 hasAuthorship W3094906946A5021488024 @default.
• W3094906946 hasAuthorship W3094906946A5028384284 @default.
• W3094906946 hasAuthorship W3094906946A5028741920 @default.

• next